Peer-Reviewed Publications

    Bridging inhaled aerosol dosimetry to physiologically based pharmacokinetic modeling for toxicological assessment: nicotine delivery systems and beyond

    Kolli, A. R.; Kuczaj, A. K.; Martin, F.; Hayes, A. W.; Peitsch, M. C.; Hoeng, J.

    Published
    Jan 6, 2020
    DOI
    10.1080/10408444.2019.1692780
    PMID
    31903848
    Link to publication
    Topic
    Summary

    One of the challenges for toxicological assessment of inhaled aerosols is to accurately predict their deposited and absorbed dose. Transport, evolution, and deposition of liquid aerosols are driven by complex processes dominated by convection-diffusion that depend on various factors related to physics and chemistry. These factors include the physicochemical properties of the pure substance of interest and associated mixtures, the physical and chemical properties of the aerosols generated, the interplay between different factors during transportation and deposition, and the subject-specific inhalation topography. Several inhalation-based physiologically based pharmacokinetic (PBPK) models have been developed, but the applicability of these models for aerosols has yet to be verified. Nicotine is among several substances that are often delivered via the pulmonary route, with varied kinetics depending upon the route of exposure. This was used as an opportunity to review and discuss the current knowledge and state-of-the-art tools combining aerosol dosimetry predictions with PBPK modeling efforts. A validated tool could then be used to perform for toxicological assessment of other inhaled therapeutic substances. The Science Panel from the Alliance of Risk Assessment have convened at the "Beyond Science and Decisions: From Problem Formulation to Dose-Response Assessment" workshop to evaluate modeling approaches and address derivation of exposure-internal dose estimations for inhaled aerosols containing nicotine or other substances. The discussion involved PBPK model evaluation criteria, challenges, and choices that arise in such a model design, development, and application as a computational tool for use in human toxicological assessments.

    Related Publications

    Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

    Aerosol Chemistry

    Air quality assessment during indoor use of the Tobacco Heating System 2.2

    Aerosol Chemistry

    Air quality assessment during indoor use of the Tobacco Heating System THS 2.2

    Aerosol Chemistry

    Indoor Air Chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

    Aerosol Chemistry

    Indoor air chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

    Aerosol Chemistry

    Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

    Aerosol Chemistry

    Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

    Aerosol Chemistry

    Air quality assessment during indoor use of the Tobacco Heating System 2.2

    Aerosol Chemistry

    Air quality assessment during indoor use of the Tobacco Heating System THS 2.2

    Aerosol Chemistry

    Indoor Air Chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

    Aerosol Chemistry

    Indoor air chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

    Aerosol Chemistry

    Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

    Aerosol Chemistry

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.